

# Health-Related Quality of Life of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Received Zanubrutinib or Ibrutinib

## FULL TITLE

Health-Related Quality of Life Outcomes Associated With Zanubrutinib Versus Ibrutinib Monotherapy in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Results From the Randomized Phase 3 ALPINE Trial

## SUMMARY DATE

June 2022

## KEY TAKEAWAYS

In the ALPINE trial, zanubrutinib was associated with improvements in health-related quality of life in patients with relapsed or refractory CLL/SLL compared with ibrutinib.

## PHONETICS

How to say medical terms used in this summary



### BRUKINSA

<BROO-kin-sah>

### Tyrosine kinase inhibitor

<TY-ruh-seen KY-nays in-HIH-bih-ter>

### Ibrutinib

<eye-BROO-ti-nib>

### Zanubrutinib

<ZAN-ue-broo-ti-nib>

### Lymphocytic leukemia

<LIM-foh-SIH-tik loo-KEE-mee-uh>

Zanubrutinib is not approved outside of China as a therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma, which is discussed in this summary. This summary reports the results of a planned interim analysis of the study, meaning the study is still ongoing.

## What is chronic lymphocytic leukemia or small lymphocytic lymphoma?

- ▶ Chronic lymphocytic leukemia or small lymphocytic lymphoma (also known as CLL and SLL) are a type of slow-growing blood cancer where an increased number of mature, but cancerous, lymphocytes are found in the blood and bone marrow, and/or in the lymph nodes
  - ▶ Lymphocytes are a type of white blood cell that normally produce antibodies that defend the body from germs
- ▶ CLL and SLL are essentially the same disease, the only difference being the location in the body where the cancer primarily occurs
  - ▶ CLL is when most of the cancer cells are in the bloodstream and the bone marrow. SLL is when most of the cancer cells are in the lymph nodes and are rare in the blood
- ▶ Relapsed CLL means the cancer has come back after getting better with prior treatment; refractory CLL means the cancer did not respond to treatment
- ▶ Patients with relapsed or refractory CLL/SLL often feel they have worse physical, mental, and social well-being due to the disease itself or from the side effects of treatment

## What is zanubrutinib?

- ▶ Zanubrutinib, sold under the brand name BRUKINSA®, is a Bruton tyrosine kinase (BTK for short) inhibitor
  - ▶ BTK is a protein found in a type of white blood cell that plays a role in cell development and survival. Zanubrutinib works by blocking BTK function, which can keep cancer cells from growing and lead to death of cancer cells

## What was the aim of this research?


- ▶ An aim of the ALPINE study was to look at health-related quality of life (HRQoL) of patients with relapsed or refractory CLL/SLL who received zanubrutinib compared with QoL of patients who received ibrutinib
  - ▶ Ibrutinib is also a BTK inhibitor that is sold under the brand name IMBRUVICA®
- ▶ Health-related QoL is a measure of a person's self-reported well-being; it can include opinions about their physical health, emotional well-being, and ability to take part in daily activities
  - ▶ Patients completed questionnaires at various times during the study that assessed the impact of CLL/SLL and treatment on their health and QoL

## What does this summary describe?

- ▶ This summary describes changes in patient-reported HRQoL from the start of the study (baseline) to 6 months and 1 year of treatment, specifically:
  - ▶ Overall HRQoL
  - ▶ Ability to perform activities of daily life
  - ▶ CLL/SLL symptoms or side effects (diarrhea, tiredness, etc.) experienced

## STUDY DETAILS

### Who took part in the study?



## What were the results of the study?

After  **6 months,**

Results showed that patients taking **zanubrutinib** compared with those taking **ibrutinib** had

Better improvements in



General health



Physical activities

Greater reductions in



Feeling tired



Pain



Feeling sick to the stomach



Diarrhea

After  **1 year,**

Both groups saw similar results in



General health



Physical activities



Work activities

Compared with patients taking **ibrutinib**, patients taking **zanubrutinib** had fewer incidents of



Diarrhea




Pain

## Who sponsored the study?

This study was sponsored by BeiGene, Ltd. BeiGene would like to thank the trial investigators, site support staff, and especially the patients who took part in the study. This summary was prepared by Regina Switzer, PhD (BeiGene, Ltd.).

## Where is zanubrutinib in the developmental timeline?



## Are there plans for additional studies?

This study is ongoing and has not yet been completed. Other zanubrutinib studies are currently ongoing and can be viewed by going to:

<https://www.beigene.com/our-science-and-medicines/pipeline>

## Additional study information

For detailed study information, go to:

<https://clinicaltrials.gov/ct2/show/NCT03734016>

For more information about scientific studies in general, go to:

<https://clinicaltrials.gov/ct2/about-studies/learn>

## Need additional information?

**Email:** [info@beigene.com](mailto:info@beigene.com)

**Website:** <https://www.beigene.com>

**Address:** BeiGene, USA  
1900 Powell Street, Suite 500  
Emeryville, CA 94608

**Phone:** 1 (877) 828-5568

This summary only contains information from the scientific abstract, available by scanning the following QR code

